PCC Rokita stock: fair value
PCR.WAThe fair value of PCC Rokita under our model is $16.86, the price is 8% below.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Fairly valuedIn our model the price counts as cheap below $14.05 and expensive above $21.08 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $11.72 (cash-flow model) and $22.00 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 10.6%. At 11.6% the fair value would be $15.96, at 9.6% it would be $18.21.
Where the number comes from
Half from the cash-flow model, half from earnings times the industry P/E (15.7).
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 5.6%. Discounted at 10.6% (floor: government bond yield 5.6% plus 5 percentage points, since beta 0.8 times the risk premium would give less); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $11.72 per share: free cash flow for the next ten years, each year discounted to today at 10.6%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 10.6%) |
|---|---|---|---|---|
| 2026 | $20.43M | extrapolated at −22.6% | 0.9045 | $18.47M |
| 2027 | $17.54M | extrapolated at −14.1% | 0.8181 | $14.35M |
| 2028 | $16.09M | extrapolated at −8.2% | 0.7400 | $11.91M |
| 2029 | $15.44M | extrapolated at −4.1% | 0.6693 | $10.33M |
| 2030 | $15.25M | extrapolated at −1.2% | 0.6054 | $9.23M |
| 2031 | $15.38M | extrapolated at 0.8% | 0.5475 | $8.42M |
| 2032 | $15.72M | extrapolated at 2.3% | 0.4952 | $7.79M |
| 2033 | $16.23M | extrapolated at 3.2% | 0.4479 | $7.27M |
| 2034 | $16.87M | extrapolated at 3.9% | 0.4052 | $6.84M |
| 2035 | $17.62M | extrapolated at 4.4% | 0.3665 | $6.46M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $101.06M |
| Terminal value: cash flow 2035 × (1 + 5.6%) / (10.6% − 5.6%) | $371.96M |
| Present value of terminal value (× 0.3665) | $136.31M |
| Equity value (sum plus present value of terminal value) | $237.37M |
| Shares (diluted) | 20.26M |
| Value per share (equity value divided by shares) | $11.72 |
| Earnings per share, last twelve months | $1.41 |
| × 15.7 (industry P/E) | $22.00 |
| Fair value (average of both parts) | $16.86 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = PLN 3.9742)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.